SRPT Duchenne Drug trial hits 5 year mark, page-28

Of course all of our concerns are "purely about getting trials (HD, AD and PD) designed, funded and underway" and have been for a very long time, until many now are wondering how that can be possible considering the past and current struggles just to reach late-stage trials for HD. Prana would not be the first small biotech to obtain approval and then fail to have their drug easily accepted by payors and physicians for their patients, especially by any who are familiar with the FDA's present reservations. It's no stretch for negatives to wonder how Prana plans to handle it. I'm betting that anyone familiar with Prana (who doesn't have a sales force because they've never needed it) is also wondering. Prana will have to explain how they will manage it to the FDA or any other drug regulatory agency.

The author's error of incorrect attribution of Prana being the inventor of the Alzheimer's dish instead of identifying Dr. Kim as the real inventor cannot be seen as a positive for unwitting potential Prana buyers. Dr. Kim and Dr Tanzi are colleagues in their work at Cure Alzheimer's Fund. Tanzi has spoken of Kim as the inventor of the dish. The question is: Why has the author not been requested to make a correction? Anyone who has any exposure to Prana for any length of time knows their MOA - let's wait.